Regeneron Pharmaceuticals D
D
REGN
579.13
USD
-7.33
(-1.25%)
مغلق
حجم التداول
17,791
الربح لكل سهم
36
العائد الربحي
0.45
P/E
15
حجم السوق
61,380,507,285
الأخبار المقالات
العنوان: Regeneron Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).